Michael Keating

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years
    Ahmed Aribi
    Department of Leukemia, Unit 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 31:939-45. 2007
  2. pmc Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Mol Cancer 12:50. 2013
  3. ncbi request reprint Management of chronic lymphocytic leukemia: a changing field
    Michael J Keating
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Rev Clin Exp Hematol 6:350-65; discussion 449-50. 2002
  4. ncbi request reprint Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    Michael J Keating
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4079-88. 2005
  5. ncbi request reprint Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia
    M J Keating
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 61, Houston, TX 77030, USA
    Leuk Lymphoma 43:1755-62. 2002
  6. ncbi request reprint Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
    Michael Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 4:220-7. 2004
  7. ncbi request reprint Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Michael J Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3554-61. 2002
  8. ncbi request reprint Ofatumumab
    Michael J Keating
    Michael J Keating is at 1515 Holcombe Boulevard, Unit 428, Houston, Texas 77030, USA
    Nat Rev Drug Discov 9:101-2. 2010
  9. ncbi request reprint Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Stefan Faderl
    Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 105:940-7. 2005
  10. doi request reprint Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009

Collaborators

Detail Information

Publications121 found, 100 shown here

  1. ncbi request reprint T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years
    Ahmed Aribi
    Department of Leukemia, Unit 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 31:939-45. 2007
    ..Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients...
  2. pmc Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Mol Cancer 12:50. 2013
    ....
  3. ncbi request reprint Management of chronic lymphocytic leukemia: a changing field
    Michael J Keating
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Rev Clin Exp Hematol 6:350-65; discussion 449-50. 2002
  4. ncbi request reprint Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    Michael J Keating
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4079-88. 2005
    ..A chemoimmunotherapy program consisting of fludarabine, cyclophosphamide, and rituximab (FCR) was developed with the goal of increasing the complete remission (CR) rate in previously untreated CLL patients to >/= 50%...
  5. ncbi request reprint Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia
    M J Keating
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 61, Houston, TX 77030, USA
    Leuk Lymphoma 43:1755-62. 2002
    ..Fludara-refractory patients are a poor prognosis group and need more effective therapeutic regimens and well-designed infection prophylactic regimens...
  6. ncbi request reprint Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
    Michael Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 4:220-7. 2004
    ..Because high response rates and few complications are observed in previously untreated patients, the use of alemtuzumab earlier in therapy may provide optimum benefit to patients...
  7. ncbi request reprint Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Michael J Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3554-61. 2002
    ..Alemtuzumab induced significant responses in these patients with clinical benefit in the majority and with acceptable toxicity in a high-risk group...
  8. ncbi request reprint Ofatumumab
    Michael J Keating
    Michael J Keating is at 1515 Holcombe Boulevard, Unit 428, Houston, Texas 77030, USA
    Nat Rev Drug Discov 9:101-2. 2010
    ..Ofatumumab (Arzerra; Genmab/GlaxoSmithKline) - a fully human cytolytic monoclonal antibody that is specific for CD20 - was approved by the US FDA for the treatment of chronic lymphocytic leukaemia in October 2009...
  9. ncbi request reprint Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Stefan Faderl
    Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 105:940-7. 2005
    ..The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy...
  10. doi request reprint Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009
    ..To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms...
  11. ncbi request reprint Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4070-8. 2005
    ..The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response...
  12. ncbi request reprint Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 106:1099-109. 2006
    ..Topotecan-cytarabine regimens have shown encouraging results in higher-risk MDS. The aim of this study was to analyze the long-term results with topotecan-cytarabine versus other intensive chemotherapy regimens in higher-risk MDS...
  13. ncbi request reprint Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2177-87. 2002
    ..We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival...
  14. ncbi request reprint Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:68-75. 2004
    ..Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib versus other) on survival...
  15. ncbi request reprint A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1234-41. 2003
    ....
  16. ncbi request reprint Outcome of patients with acute myelogenous leukemia after second salvage therapy
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Cancer 104:547-54. 2005
    ..The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival...
  17. ncbi request reprint Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
    Apostolia Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1481-7. 2003
    ....
  18. ncbi request reprint Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2636-42. 2003
    ..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
  19. ncbi request reprint Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    Hagop Kantarjian
    Department of Leukemia, Anderson Cancer Center, Houston, TX, USA
    Blood 102:2379-86. 2003
    ..03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance...
  20. ncbi request reprint Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    Deborah A Thomas
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 123:436-41. 2003
    ..Thalidomide analogues with more potent immunomodulatory activities and more favourable toxicity profiles may offer more promise as anti-AML therapy...
  21. ncbi request reprint A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:337-45. 2006
    ..The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL...
  22. doi request reprint Late relapses in acute myeloid leukemia: analysis of characteristics and outcome
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 51:778-82. 2010
    ..4 months (range, 1-39). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone...
  23. doi request reprint Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment
    William G Wierda
    Department of Leukemia and Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:1637-43. 2009
    ..Identifying pretreatment patient characteristics or prognostic factors associated with clinical outcomes is important for counseling patients, conducting clinical research, and evaluating trial results...
  24. ncbi request reprint Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2788-801. 2004
    ..The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) program, with a median follow-up time of 63 months...
  25. ncbi request reprint T-cell prolymphocytic leukemia: a single-institution experience
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Lymphoma Myeloma 6:234-9. 2005
    ..The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias...
  26. ncbi request reprint Pregnancy among patients with chronic myeloid leukemia treated with imatinib
    Patricia Ault
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1204-8. 2006
    ..Imatinib has potential teratogenicity in animals, but the effect of exposure to imatinib during conception and pregnancy in humans is not known...
  27. ncbi request reprint Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia
    Anna Rogers
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Blood 103:2799-801. 2004
    ..These data support the conclusion that PB plasma is enriched by tumor-specific DNA and can replace BM cells for studying genomic abnormalities...
  28. ncbi request reprint Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2212-7. 2003
    ..The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown...
  29. ncbi request reprint Differences in CD33 intensity between various myeloid neoplasms
    Iman Jilani
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 118:560-6. 2002
    ..There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias...
  30. ncbi request reprint Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
    Susan O'Brien
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1816-9. 2008
    ..004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770...
  31. doi request reprint Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:1933-52. 2008
    ..In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon...
  32. ncbi request reprint Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2478-83. 2007
    ..However, the profound immunosuppression caused by alemtuzumab has been associated with infectious complications...
  33. ncbi request reprint Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:522-8. 2003
    ..Decitabine is a hypomethylating agent that has shown encouraging preliminary anti-CML activity. This study evaluated the activity and toxicity of decitabine in different phases of CML...
  34. doi request reprint Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:4422-9. 2010
    ..In summary, the prognosis of most patients (72%) ≥ 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ≥ 30%; median survival < 6 months)...
  35. ncbi request reprint Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
    William G Wierda
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:4679-85. 2007
    ..This prognostic model may help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design...
  36. ncbi request reprint Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Blood 106:4303-7. 2005
    ..These data reflect the complexity by which angiogenic factors may affect the clinical behavior of patients with ALL, and this complexity should be considered in any therapeutic strategy incorporating antiangiogenic agents...
  37. ncbi request reprint Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1248-52. 2003
    ..However, the impact of elevated TA on the course of patients with chronic phase chronic myeloid leukemia (CP-CML) is unknown...
  38. ncbi request reprint Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leuk Lymphoma 47:1062-8. 2006
    ..The observation that patients can be cured of APL without the use of chemotherapy should encourage further study of 'targeted' therapy in APL and in other leukemias...
  39. ncbi request reprint Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia
    Charles Koller
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, USA
    Blood 108:1001-6. 2006
    ..95 mg/L had significantly shorter survival than those with lower values. Plasma TPO and beta2-M may be useful for the prediction of clinical behavior in CLL and may replace the need for the determination of IgV(H) mutation status...
  40. ncbi request reprint Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, 77030, USA
    Cancer Chemother Pharmacol 50:237-42. 2002
    ..We conducted a pilot study to assess the safety of the soluble TNF receptor, etanercept (p75 TNFR:Fc; Enbrel) in patients with refractory hematologic malignancies...
  41. ncbi request reprint Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia
    Jessica C Pahler
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:4570-7. 2003
    ..The compound is being evaluated currently in Phase II and III clinical trials. Here we characterized the effects and mechanisms of action of bortezomib in cells obtained from patients with chronic lymphocytic leukemia (CLL)...
  42. ncbi request reprint Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia
    William G Wierda
    Department of Leukaemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 120:452-6. 2003
    ..The role of IL-8 inhibitors in the treatment of patients with CLL should be explored...
  43. ncbi request reprint Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
    Hagop M Kantarjian
    Departments of Leukemia, Experimental Therapeutics, and Breast and Head and Neck, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1167-73. 2003
    ..Encouraging activity was observed in acute leukemia...
  44. ncbi request reprint Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
    Iman Jilani
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 102:3514-20. 2003
    ..The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation...
  45. ncbi request reprint The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia
    Stacey Ruiz
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Box 173, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 5:1836-43. 2006
    ..Our results show that NPI-0052 is a more effective proapoptotic agent than bortezomib in isolated CLL cells and suggest that the chemical properties of NPI-0052 might also make it an effective therapeutic agent in CLL patients...
  46. ncbi request reprint Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia
    Ehab Atallah
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:3547-51. 2007
    ..Guidelines for reporting adverse events in leukemia studies should be revisited...
  47. doi request reprint A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia
    Nitin Jain
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:4533-9. 2009
    ..Thus, we adapted this approach as consolidation therapy in patients with CLL responding to chemoimmunotherapy...
  48. doi request reprint Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:3818-23. 2011
    ..Median survival duration has not been reached (range, 2+-64+ months). Treatment with cladribine followed by rituximab is effective tk;4and may increase CR rate. This study was registered at www.clinicaltrials.gov as NCT00412594...
  49. ncbi request reprint Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma
    Maha Ahmed
    Department of Hematopathology, M D Anderson Cancer Center, The University of Texas, Houston, TX 77030 4095, USA
    Eur J Haematol 71:174-8. 2003
    ..However, cytogenetic analysis in MM is frequently difficult because of poor yield of informative metaphases and the disease is frequently patchy, which complicates fluorescent in situ hybridization studies...
  50. ncbi request reprint Mature T-cell leukemias
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1808-18. 2005
    ..Herein, we review the clinical and pathological features of mature T-cell leukemias...
  51. ncbi request reprint Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
  52. ncbi request reprint Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:81-5. 2003
    ..Delaying SCT until the disease demonstrates resistance to other strategies (e.g., imatinib mesylate or interferon-alpha) entails the risk of the development of a sudden blastic phase, which may not permit enough time to perform a SCT...
  53. doi request reprint The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia
    Ravin Garg
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3531-7. 2012
    ..Although 13q deletion as the sole abnormality has been found to confer a favorable prognosis, there are little data as to whether there is a difference in prognostic value between monoallelic versus biallelic deletion of 13q...
  54. pmc Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate
    Yumin Hu
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:2732-41. 2010
    ..Such a combination strategy may be an effective therapeutic regimen and have potential clinical application in leukemia...
  55. doi request reprint Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 50:27-31. 2009
    ..Herein, the available data regarding the prevalence and clinical relevance of MRD after therapy for HCL is reviewed...
  56. doi request reprint Aurora-A kinase nuclear expression in chronic lymphocytic leukemia
    Kedar V Inamdar
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 21:1428-35. 2008
    ..Thus, Aurora-A kinase overexpression in chronic lymphocytic leukemia may be involved in the genesis of chromosomal abnormalities and is a potential target for therapeutic intervention...
  57. ncbi request reprint Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia
    Susan O'Brien
    Department of Leukemia and Bioimmunotherapy, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:2024-32. 2002
    ..The objectives of this study were to evaluate the efficacy and toxicity profiles of a combination regimen of simultaneous HHT and IFN-alpha therapy in patients with chronic-phase CML who were not exposed previously to either agent...
  58. ncbi request reprint Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  59. doi request reprint Forodesine: review of preclinical and clinical data
    Aref Al-Kali
    Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Future Oncol 6:1211-7. 2010
    ..Early clinical trials show that forodesine has promise as a single agent for the treatment of relapsed/refractory hematologic malignancies, and combination therapies might be warranted to improve clinical results...
  60. pmc Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells
    Ping Li
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e11859. 2010
    ..Because Stat3 is constitutively activated in CLL and sequence analysis revealed that the ROR1 promoter harbors gamma-interferon activation sequence-like elements typically activated by Stat3, we hypothesized that Stat3 activates ROR1...
  61. doi request reprint Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia
    Deqin Ma
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 11:S17-24. 2011
    ..The frequent 2p25.3 gain involving the ACP1 and MYCN genes may help define the critical region of 2p that contributes to pathogenesis of CLL together with other chromosomal abnormalities...
  62. pmc Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
    Aref Al-Kali
    Leukemia Department, UT MD Anderson Cancer Center, Houston, Texas, USA
    J Blood Med 1:115-22. 2010
    ..This type of relatively nontoxic regimen is being investigated in elderly patients who may not tolerate standard combination chemoimmunotherapies...
  63. ncbi request reprint CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype
    Ellen Schlette
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Arch Pathol Lab Med 127:561-6. 2003
    ..CD79b is a relatively newly characterized B-cell marker that is expressed in a minority of chronic lymphocytic leukemia (CLL) cases...
  64. ncbi request reprint Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome
    Chung Wu Lin
    Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd, P O Box 72, Houston, TX 77030, USA
    Leuk Res 26:551-9. 2002
    ..Our results illustrate differences in proliferation and apoptosis between acute and chronic leukemias and MDS. These differences may have diagnostic and therapeutic implications...
  65. ncbi request reprint Chemoimmunotherapy of chronic lymphocytic leukemia
    Constantine S Tam
    Leukemia Department, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77025, USA
    Best Pract Res Clin Haematol 20:479-98. 2007
    ..We review the evolution of modern chemoimmunotherapy for CLL, and discuss current research directions for further refining the potency of these regimens...
  66. ncbi request reprint Monoclonal antibodies in chronic lymphocytic leukemia
    Alessandra Ferrajoli
    University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, PO Box 301402, Houston, TX 77230 1402, USA
    Expert Rev Anticancer Ther 6:1231-8. 2006
    ....
  67. ncbi request reprint Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors
    Gautam Borthakur
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:800-5. 2007
    ..Thus, the incidence of IA among CLL patients treated with FCR was comparable with historical rates. The diagnosis of AIHA can be considered even if the DAT is negative. Pre-existing AIHA need not preclude front-line FCR therapy...
  68. pmc Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology
    Lynne V Abruzzo
    University of Texas M D Anderson Cancer Center, Department of Hematopathology, Box 72, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Mol Diagn 9:546-55. 2007
    ..Thus, we can classify cases with 95% accuracy based on the expression of as few as three genes...
  69. ncbi request reprint Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 137:355-63. 2007
    ..These results demonstrate a potent graft-versus-leukaemia effect that can overcome the adverse prognostic effect of ZAP-70 expression...
  70. ncbi request reprint The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases
    Yang O Huh
    Department of Hematopathology, MD Anderson Cancer Centre, The University of Texas, Houston, TX 77030, USA
    Br J Haematol 136:220-8. 2007
    ..However, these neoplasms also differ from CLL cytologically and in their immunophenotype...
  71. ncbi request reprint Fine-needle aspiration biopsy findings in patients with small lymphocytic lymphoma transformed to hodgkin lymphoma
    F Catrina Reading
    Departments of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Pathol 128:571-8. 2007
    ..In these cases, histologic confirmation is always recommended, not only to differentiate HL transformation from other entities but also for subclassification of HL...
  72. doi request reprint Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity
    Amar Safdar
    Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:383-7. 2008
    ....
  73. doi request reprint Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 111:5291-7. 2008
    ..According to our experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL...
  74. doi request reprint Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients
    Constantine S Tam
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 141:36-40. 2008
    ..Leukemic CD20 expression differed significantly between FISH subtypes. Patients with trisomy 12 CLL showed strong leukemic cell CD20 expression and had a high rate of response to rituximab-based therapy...
  75. doi request reprint Phase I trial of nelarabine in indolent leukemias
    Varsha Gandhi
    Department of Experimental Therapeutics, Box 71, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:1098-105. 2008
    ..To test whether nelarabine is an effective agent for indolent leukemias and to evaluate whether there is a relationship between cellular pharmacokinetics of the analog triphosphate and clinical responses...
  76. pmc Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1370-8. 2008
    ..In the current study, the authors addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes...
  77. ncbi request reprint Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
    Marco Montillo
    Department of Oncology Haematology, Division of Haematology, Niguarda Ca Granda Hospital, Piazza dell Ospedale Maggiore 3, 20161 Milan, Italy
    Cancer 97:114-20. 2003
    ..To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL)...
  78. doi request reprint The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:721-30. 2008
    ..Serum beta(2) microglobulin (beta2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML)...
  79. doi request reprint Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...
  80. ncbi request reprint Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4648-56. 2007
    ..We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors...
  81. doi request reprint Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    Constantine S Tam
    Departments ofLeukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:975-80. 2008
    ..5% per year for the third year onward. In a multivariate analysis of patients receiving fludarabine-based therapy at our center, FCR therapy emerged as the strongest independent determinant of survival...
  82. pmc Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal
    Mazin A Moufarij
    Department of Experimental Therapeutics Unit 71, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 108:4187-93. 2006
    ..Our findings support a role of fludarabine-mediated DNA repair inhibition as a mechanism critical for the cytotoxic synergy of the 2 drugs...
  83. ncbi request reprint Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray
    Larissa Belov
    Medsaic Pty Ltd, Suite 145, Level1, National Innovation Centre, Australian Technology Park, Garden Street, Eveleigh, Australia
    Br J Haematol 135:184-97. 2006
    ..This technique may be a useful adjunct to flow cytometry and other methods when an extensive phenotype of the leukaemia cell is desired for clinical trials, research and prognostic factor analysis...
  84. ncbi request reprint Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2195-200. 2004
    ..The aim of the current analysis was to evaluate retrospectively the efficacy and safety of (90)Y ibritumomab tiuxetan in patients with Richter syndrome (RS)...
  85. ncbi request reprint Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias
    Varsha Gandhi
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, 77030, USA
    Clin Cancer Res 9:6335-42. 2003
    ....
  86. ncbi request reprint Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease
    Apostolia M Tsimberidou
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 44:1719-25. 2003
    ..Human antimouse antibody (HAMA) and/or human antiricin antibody (HARA) development was documented in 2 patients. Anti-B4 blocked ricin was well tolerated but had limited activity in patients with residual CLL after chemotherapy...
  87. ncbi request reprint Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 123:850-7. 2003
    ..The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study...
  88. ncbi request reprint Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens...
  89. ncbi request reprint The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate
    Simona Gatto
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Haematologica 88:853-63. 2003
    ..We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction...
  90. ncbi request reprint Phase II study of alemtuzumab in chronic lymphoproliferative disorders
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:773-8. 2003
    ..Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders...
  91. ncbi request reprint Emerging information on the use of rituximab in chronic lymphocytic leukemia
    Michael J Keating
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 29:70-4. 2002
    ....
  92. ncbi request reprint Rituximab in B-cell disorders other than non-Hodgkin's lymphoma
    Andre Bosly
    Cliniques Universitaires, Mont Godinne Yvoir, Belgium
    Anticancer Drugs 13:S25-33. 2002
    ..Available data thus indicate that rituximab can be an effective therapy in a wide range of CD20+ lymphoid disorders...
  93. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients...
  94. ncbi request reprint Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1033-41. 2003
    ....
  95. ncbi request reprint Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 101:3413-5. 2003
    ..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
  96. ncbi request reprint UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes
    Takahiro Yamauchi
    Department of Experimental Therapeutics, Box 71, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 1:287-94. 2002
    ..Our findings suggest that UCN-01 may be a good candidate for combination strategies of cancer treatment...
  97. ncbi request reprint Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    Alvaro Aguayo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1923-30. 2002
    ..Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors...
  98. ncbi request reprint In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
    Barbara Scappini
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 94:2653-62. 2002
    ..In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML...
  99. ncbi request reprint Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 43:767-72. 2002
    ..FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders...
  100. ncbi request reprint The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:1215-9. 2002
    ..005). We conclude that the TNF-alpha level serves as a prognostic factor in patients with CLL and that inhibition of TNF-alpha in these patients could have therapeutic importance...
  101. ncbi request reprint Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
    ..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease...